title: Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
abstract: The aim of the study was to retrospectively assess the efficacy and safety of low-dose metronomic oral capecitabine in pretreated or frail patients with recurrent colorectal cancer. Patients with recurrent colorectal cancer and prior treatment with fluoropyrimidines, oxaliplatin, and irinotecan or unable to receive standard chemotherapy because of toxicity concerns were included. Treatment consisted of oral capecitabine 1,500 mg daily until disease progression or unacceptable toxicity. Response rates were determined according to RECIST criteria. The end points were disease control rate [(DCR) consisting of complete response, partial response (PR), and stable disease (SD)], overall survival (OS), and safety. Sixty-eight patients, median age 72.5 years, were treated. The median number of previous treatments was 2 (range 0-5). Sixty-two percent of patients had received ≥2 previous lines of treatment. The overall DCR was 26%, PR in 2 (3%) and SD in 14 (23%). Nineteen percent of patients were progression free for at least 6 months. In an exploratory analysis, there was a significant relation of performance status with DCR (HR = 3.3; P = 0.05). The median OS was 8 months. DCR was associated with a longer survival (HR = 0.4; P < 0.01). Grade 3 toxicities included anemia (1), diarrhea (1), and hand-foot syndrome (1). There were no cases of grade 4 toxicity or treatment-related deaths. Metronomic capecitabine was moderately active and well-tolerated in pretreated or frail patients with recurrent colorectal cancer.
authors: Clinical and Molecular Medicine Department, Sapienza University, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy, adriana.romiti@uniroma1.it.
authors: Adriana
authors: A
authors: Romiti
authors: Concetta Elisa
authors: CE
authors: Onesti
authors: Michela
authors: M
authors: Roberto
authors: Viola
authors: V
authors: Barucca
authors: Silverio
authors: S
authors: Tomao
authors: Chiara
authors: C
authors: D'Antonio
authors: Valeria
authors: V
authors: Durante
authors: Annalisa
authors: A
authors: Milano
authors: Rosa
authors: R
authors: Falcone
authors: Roberta
authors: R
authors: Di Rocco
authors: Riccardo
authors: R
authors: Righini
authors: Paolo
authors: P
authors: Marchetti
mesh_terms: D059250:Administration, Metronomic; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000069287:Capecitabine / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000069287:Capecitabine
references: J Clin Oncol. 2008 Oct 20;26(30):4899-905
references: 18794539
references: J Clin Oncol. 2014 Apr 1;32(10):1031-9
references: 24590654
references: J Clin Oncol. 2008 Jan 20;26(3):463-7
references: 18202421
references: J Clin Invest. 2000 Apr;105(8):1045-7
references: 10772648
references: Med Oncol. 2014 Mar;31(3):870
references: 24510794
references: J Clin Oncol. 2010 Feb 10;28(5):723-30
references: 20026801
references: Clin Cancer Res. 2009 Feb 1;15(3):1046-51
references: 19188178
references: Angiogenesis. 2012 Jun;15(2):275-86
references: 22382585
references: J Clin Invest. 2000 Apr;105(8):R15-24
references: 10772661
references: Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8
references: 19168635
references: Ann Oncol. 2002 Jan;13(1):73-80
references: 11863115
references: Cancer Res. 2007 Apr 15;67(8):3560-4
references: 17440065
references: Cancer Immunol Immunother. 2007 May;56(5):641-8
references: 16960692
references: Cancer Chemother Pharmacol. 2013 Jul;72(1):13-33
references: 23475105
references: Lancet Oncol. 2001 Dec;2(12):733-40
references: 11902515
references: Cancer Chemother Pharmacol. 2007 Aug;60(3):351-6
references: 17111120
references: Br J Cancer. 2011 Jun 7;104(12):1822-7
references: 21587257
references: Onkologie. 2007 Dec;30(12):629-35
references: 18063875
references: Cancer Res. 2000 Apr 1;60(7):1878-86
references: 10766175
references: Nat Rev Cancer. 2004 Jun;4(6):423-36
references: 15170445
references: Cancer Lett. 2014 Jul 28;349(2):128-35
references: 24746899